Gene therapy protocols should not be subject to proprietary restraints during FDA review -- RAC subcmte.
GENE THERAPY PROTOCOLS SHOULD NOT BE SUBJECT TO PROPRIETARY RESTRAINTS during FDA review, the National Institutes of Health Recombinant DNA Advisory Committee Ad Hoc Review Committee recommends in a report submitted to NIH Director Harold Varmus, MD, in September and published in the Nov. 15 Federal Register. The ad hoc group's recommendations will be discussed at a Dec. 4-5 meeting of the RAC at NIH. Chaired by Inder Verma, PhD, The Salk Institute, the ad hoc committee was convened to address oversight of gene transfer protocols in order to make recommendations to Varmus on the future operations of the RAC ("The Pink Sheet" Sept. 4, p. 5).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth